Four hundred forty-three patients with chronic painful neuropathy were treated with 600 mg per day of alphalipoic acid (ALA) for a mean period of five years.

Eisai expects to make contributions to patients with diabetic neuropathy in the region through the availability of Methycobal.

Contributions cover acute neuropathies, chronic inflammatory demyelinating neuropathy and its variants, nonsystemic vasculitic neuropathy, dysimmune neuropathy, autoimmune autonomic ganglionopathy, myasthenia gravis with anti-acetylcholine receptor antibodies, muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis, Lambert-Eaton myasthenic syndrome, idiopathic inflammatory myopathies, and stiff person syndrome.